A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Braun, Michael S
AffiliationPoole Hospital and Bournemouth University, Longfleet Road, Poole, Dorset BH15 2JB, UK.
MetadataShow full item record
AbstractThis randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin- and irinotecan-based regimens. Efficacy in patients with KRAS mutations was also evaluated.
CitationA randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. 2014, 50 (18):3136-44 Eur J Cancer
JournalEuropean Journal of Cancer